AAPL 169.3 -0.6047% MSFT 395.125 1.4885% GOOG 165.555 0.5558% GOOGL 163.795 0.6235% AMZN 178.86 2.2057% NVDA 830.03 -3.9339% META 439.1 2.0759% TSLA 179.995 -1.7923% TSM 134.94 -1.7475% LLY 776.75 -0.5569% V 267.29 -0.4914% AVGO 1242.86 -4.4152% JPM 191.86 0.0626% UNH 484.11 0.0848% NVO 129.21 0.7014% WMT 58.82 -0.893% LVMUY 164.02 -0.0792% XOM 116.06 -1.8686% LVMHF 822.33 -0.4443% MA 442.07 -2.0235%
Last update at 2024-05-01T20:03:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -37.28284M | -34.76188M | -26.07844M | -12.44646M | -13.36810M |
| Minority interest | - | - | - | - | - |
| Net income | -36.74254M | -34.80571M | -26.21084M | -11.71263M | -12.63926M |
| Selling general administrative | 8.88M | 9.94M | 8.80M | 6.25M | 7.07M |
| Selling and marketing expenses | 4.34M | 3.71M | 3.09M | 1.46M | 1.53M |
| Gross profit | -0.81670M | 1.46M | 0.37M | 1.87M | 1.10M |
| Reconciled depreciation | 1.64M | 2.71M | 2.33M | 0.92M | 0.73M |
| Ebit | -34.56673M | -23.10232M | -21.49452M | -10.97144M | -13.18024M |
| Ebitda | -22.17155M | -23.05714M | -21.38890M | -10.96158M | -13.17486M |
| Depreciation and amortization | 12.40M | 0.05M | 0.11M | 0.00986M | 0.00538M |
| Non operating income net other | - | - | 0.04M | 0.01M | 0.00334M |
| Operating income | -34.56673M | -23.10232M | -21.49452M | -10.97144M | -13.18024M |
| Other operating expenses | 24.83M | 27.41M | 25.71M | 14.47M | 16.13M |
| Interest expense | 3.26M | 4.80M | 3.40M | 0.19M | 0.19M |
| Tax provision | 0.00000M | 0.04M | 0.13M | 0.00000M | 0.00000M |
| Interest income | 0.05M | 0.05M | 0.11M | 0.00986M | 0.00538M |
| Net interest income | -3.20947M | -4.75415M | -3.29376M | -0.17769M | -0.18581M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | 0.65M | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.54030M | 0.04M | 0.13M | -0.73383M | -0.72884M |
| Total revenue | 2.61M | 4.31M | 4.21M | 3.50M | 2.95M |
| Total operating expenses | 21.40M | 24.56M | 21.86M | 12.84M | 14.28M |
| Cost of revenue | 3.42M | 2.85M | 3.85M | 1.63M | 1.85M |
| Total other income expense net | -2.71611M | -11.65956M | -4.58392M | -1.47502M | -0.18786M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -37.28323M | -34.80571M | -26.21084M | -12.44646M | -13.36810M |
| Net income applicable to common shares | -37.28284M | -34.80571M | -26.21084M | -12.44646M | -13.36810M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 25.83M | 71.67M | 49.75M | 10.42M | 8.95M |
| Intangible assets | 7.44M | 14.53M | 16.58M | 0.82M | 1.09M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.36M | 1.25M | 1.39M | 0.40M | 0.29M |
| Total liab | 18.25M | 30.45M | 28.56M | 6.13M | 5.64M |
| Total stockholder equity | 7.58M | 41.22M | 21.19M | 4.29M | 3.31M |
| Deferred long term liab | - | - | 0.11M | - | 0.16M |
| Other current liab | 2.62M | 3.59M | 3.56M | 1.90M | 1.94M |
| Common stock | 0.03M | 0.46M | 0.25M | 0.06M | 0.09M |
| Capital stock | 0.03M | 0.46M | 0.25M | 0.06M | 0.09M |
| Retained earnings | -272.82438M | -235.54154M | -200.73583M | -174.52498M | -162.07853M |
| Other liab | 0.23M | 0.38M | 0.27M | - | 0.16M |
| Good will | 0.00000M | 7.45M | 8.02M | 0.60M | 0.60M |
| Other assets | 2.80M | 4.02M | 5.00M | 0.20M | 0.26M |
| Cash | 7.44M | 36.08M | 13.36M | 2.71M | 4.57M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 10.59M | 19.92M | 7.37M | 4.94M | 4.38M |
| Current deferred revenue | 0.14M | - | 0.00981M | 0.00981M | 0.02M |
| Net debt | 7.40M | -10.90104M | 9.49M | 0.45M | -2.67702M |
| Short term debt | 7.40M | 15.02M | 1.93M | 1.97M | 0.80M |
| Short long term debt | 7.02M | 14.52M | 0.70M | 0.37M | 0.40M |
| Short long term debt total | 14.84M | 25.18M | 22.85M | 3.16M | 1.90M |
| Other stockholder equity | 281.17M | 275.71M | 219.13M | 178.78M | 165.31M |
| Property plant equipment | 4.94M | 5.92M | 5.79M | 0.13M | 1.22M |
| Total current assets | 10.66M | 39.74M | 16.89M | 6.67M | 5.78M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | 0.13M | 19.23M | -3.41444M | 2.87M | 1.62M |
| Short term investments | - | - | - | - | - |
| Net receivables | 0.51M | 1.17M | 0.65M | 3.09M | 0.37M |
| Long term debt | 4.85M | 7.18M | 19.38M | 0.33M | 0.66M |
| Inventory | 1.35M | 1.24M | 1.49M | 0.47M | 0.54M |
| Accounts payable | 0.42M | 1.31M | 1.87M | 1.06M | 1.62M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.79583M | 0.59M | 2.55M | -0.01732M | -0.01309M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.25M | 0.06M | 0.09M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -200.73583M | -174.52498M | -162.07853M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 2.80M | 4.02M | 2.47M | 0.20M | 0.26M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 15.18M | 31.92M | 32.86M | 3.75M | 3.17M |
| Capital lease obligations | 2.95M | 3.48M | 2.77M | 2.46M | 0.84M |
| Long term debt total | - | - | 19.38M | 0.33M | 0.66M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.59077M | -1.98361M | -1.06350M | -2.50000M | -0.13733M |
| Change to liabilities | 0.00000M | -0.48163M | -1.35157M | -1.32195M | 0.17M |
| Total cashflows from investing activities | - | -1.98361M | -1.06350M | -2.50258M | -0.13733M |
| Net borrowings | - | -0.70755M | 0.29M | -0.35833M | -0.28304M |
| Total cash from financing activities | -6.73568M | 47.45M | 34.09M | 12.17M | 13.85M |
| Change to operating activities | - | 1.34M | -0.40768M | -0.24124M | 0.08M |
| Net income | -37.28323M | -34.80571M | -26.21084M | -12.44646M | -13.36810M |
| Change in cash | -28.69653M | 22.52M | 11.21M | -1.84360M | 2.65M |
| Begin period cash flow | 36.63M | 14.11M | 2.89M | 4.74M | 2.09M |
| End period cash flow | 7.94M | 36.63M | 14.11M | 2.89M | 4.74M |
| Total cash from operating activities | -20.44970M | -21.47928M | -23.39653M | -11.50544M | -11.07400M |
| Issuance of capital stock | 4.07M | 38.81M | 25.11M | 13.06M | 14.13M |
| Depreciation | 1.64M | 2.71M | 2.33M | 0.92M | 0.73M |
| Other cashflows from investing activities | - | - | -2.20000M | 0.03M | 0.01M |
| Dividends paid | - | 7.17M | - | - | - |
| Change to inventory | -0.72855M | -2.33671M | -0.41034M | 0.07M | -0.01127M |
| Change to account receivables | 0.59M | -0.57512M | 0.44M | -0.19502M | 0.43M |
| Sale purchase of stock | - | - | 15.82M | 4.78M | 0.60M |
| Other cashflows from financing activities | -0.59077M | 23.20M | 10.55M | 0.47M | 0.38M |
| Change to netincome | - | 12.66M | 2.21M | 0.38M | 0.85M |
| Capital expenditures | 0.59M | 1.98M | 0.13M | 0.03M | 0.15M |
| Change receivables | - | - | 0.44M | -0.19502M | 0.43M |
| Cash flows other operating | - | - | 0.30M | 1.07M | -0.00813M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | 9.63M | -1.83987M | 2.63M |
| Change in working capital | -1.95193M | -2.05144M | -1.73131M | -0.87550M | 0.58M |
| Stock based compensation | 0.95M | 0.88M | 0.32M | 0.37M | 0.86M |
| Other non cash items | 16.19M | 3.99M | 2.55M | -0.00832M | 0.13M |
| Free cash flow | -21.04047M | -23.46289M | -23.52689M | -11.53726M | -11.22176M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| OPGN OpGen Inc |
0.006 1.49% | 0.41 | - | - | 1.32 | 1.58 | 5.37 | -0.7353 |
| ABT Abbott Laboratories |
0.32 0.30% | 106.29 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
-8.38 2.49% | 328.12 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
0.65 0.81% | 80.89 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
0.34 0.47% | 72.21 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.
9717 Key West Avenue, Rockville, MD, United States, 20850
| Name | Title | Year Born |
|---|---|---|
| Dr. Oliver Schacht Ph.D. | CEO, Pres & Director | 1971 |
| Mr. Johannes Bacher | Chief Operating Officer | 1969 |
| Mr. Albert Weber | CFO & Corp. Sec. | 1963 |
| Mr. Vadim Sapiro | Chief Information Officer | 1971 |
| Mr. Michael Farmer | VP of Marketing | NA |
| Ms. Faranak Atrzadeh | Chief Marketing & Scientific Affairs Officer | NA |
| Dr. G. Terrance Walker Ph.D. | Sr. VP of R&D | 1959 |
| Mr. Derek Joesting | Sr. VP of US Sales | NA |
| Dr. Arne Materna | MD & CEO of Ares Genetics GmbH | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...